Try our mobile app

Switch to company model in classical logic    *

General information

Country: FRANCE

Sector: Drug Manufacturers — General

Sanofi operates as a pharmaceutical company. The Company manufactures prescription pharmaceuticals and vaccines. Sanofi also develops cardiovascular, thrombosis, metabolic disorder, central nervous system, and oncology medicines and drugs. Sanofi serves customers worldwide.
Website: sanofi.com



Growth: Pretty weak revenue growth rate 2.5%, there is slowdown compared to average historical growth rates 3.4%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -3.4%

Profitability: LTM EBITDA margin is positive, +24.9%. On average the margin is decreasing unsteadily. Gross margin is high, +66.6%. In the last quarter the company did not beat the estimated EPS, -38.3%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.09 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 3.0%. Free cash flow yield -1.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 32.0% higher than minimum and 14.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.7x by EV / Sales multiple , the company can be 8.4% overvalued

Key Financials (Download financials)

Ticker: SNY
Share price, USD:  (-0.5%)49.13
year average price 50.56  


year start price 53.65 2023-04-28

max close price 55.77 2023-05-05

min close price 43.13 2023-10-27

current price 49.13 2024-04-26
Common stocks: 2 508 000 000

Dividend Yield:  3.0%
FCF Yield LTM: -1.6%
EV / LTM EBITDA: 11.8x
EV / EBITDA annualized: 15.6x
Last revenue growth (y/y):  2.5%
Last growth of EBITDA (y/y):  -4.1%
Historical revenue growth:  3.4%
Historical growth of EBITDA:  23.1%
EV / Sales: 2.9x
Margin (EBITDA LTM / Revenue): 24.9%
Fundamental value created in LTM:
Market Cap ($m): 123 218
Net Debt ($m): 12 284
EV (Enterprise Value): 135 502
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-25Zacks Investment Research

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

2024-04-25Seeking Alpha

Sanofi (SNY) Q1 2024 Earnings Call Transcript

2024-04-25Reuters

Sanofi Q1 profit slips on generic competition, forex effects

2024-04-23Zacks Investment Research

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

2024-04-08InvestorPlace

Sanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts

2024-04-03Reuters

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

2024-03-25Seeking Alpha

Sanofi: My Top Pick In Big Pharma

2024-03-12Seeking Alpha

Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript)

2024-03-07Reuters

Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows

2024-02-20Reuters

Sanofi's consumer healthcare spin-off attracts private equity interest, sources say
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-12
symbol SNY SNY SNY SNY SNY SNY
reportedCurrency EUR EUR EUR EUR EUR EUR
cik 0 0 0 1M 1M 1M
fillingDate 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-12
acceptedDate 2023-12-30 19:00:00 2023-09-29 20:00:00 2023-06-29 20:00:00 2023-03-31 00:00:00 2022-12-30 19:00:00 2022-09-12 07:07:29
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 22 883M 12 698M 10 682M 10 863M 11 456M 13 138M
costOfRevenue 8 201M 3 841M 3 268M 3 079M 3 734M 3 831M
grossProfit 14 682M 8 857M 7 414M 7 784M 7 722M 9 307M
grossProfitRatio 0.642 0.698 0.694 0.717 0.674 0.708
researchAndDevelopmentExpenses 3 535M 1 663M 1 630M 1 563M 1 823M 1 736M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5 510M 2 579M 2 575M 2 607M 2 895M 2 644M
otherExpenses 0 0 0 793M 637M 280M
operatingExpenses 9 045M 5 402M 5 252M 4 963M 5 355M 4 660M
costAndExpenses 17 246M 9 243M 8 520M 8 042M 9 089M 8 491M
interestIncome 330M 143M 125M 161M 120M 52M
interestExpense 1 085M 318M 202M 168M 148M 103M
depreciationAndAmortization 312M 562M 546M 920M 762M 516M
ebitda 5 949M 4 160M 2 833M 3 383M 2 711M 3 240M
ebitdaratio 0.260 0.328 0.265 0.311 0.237 0.247
operatingIncome 5 637M 3 211M 1 859M 2 463M 1 949M 2 724M
operatingIncomeRatio 0.246 0.253 0.174 0.227 0.170 0.207
totalOtherIncomeExpensesNet -2 722M -244M -303M -7M -28M -51M
incomeBeforeTax 2 915M 3 036M 1 782M 2 456M 1 921M 2 673M
incomeBeforeTaxRatio 0.127 0.239 0.167 0.226 0.168 0.203
incomeTaxExpense 872M 563M 271M 459M 407M 601M
netIncome 1 970M 2 525M 1 435M 1 995M 1 460M 2 076M
netIncomeRatio 0.086 0.199 0.134 0.184 0.127 0.158
eps 1.570 2.010 1.150 0.800 0.580 0.830
epsdiluted 1.560 2.010 1.150 0.800 0.580 0.830
weightedAverageShsOut 1 251M 1 253M 1 251M 2 499M 2 508M 2 507M
weightedAverageShsOutDil 1 260M 1 253M 1 251M 2 499M 2 508M 2 507M
link Link Link Link Link
finalLink Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-13 2022-12-31 2022-06-30
symbol SNY SNY SNY SNY SNY SNY
reportedCurrency EUR EUR EUR USD EUR EUR
cik 0 0 0 1M 0 1M
fillingDate 2023-12-31 2023-09-30 2023-06-30 2023-03-13 2022-12-31 2022-06-30
acceptedDate 2023-12-29 19:00:00 2023-09-29 20:00:00 2023-06-29 20:00:00 2023-03-13 07:38:57 2022-12-30 19:00:00 2022-06-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q2
cashAndCashEquivalents 8 710M -7 993M 7 993M 0 12 736M 6 899M
shortTermInvestments 270M 15 986M 0 0 664M 0
cashAndShortTermInvestments 8 710M 7 993M 7 993M 0 12 736M 6 899M
netReceivables 11 040M 0 353M 0 374M 8 406M
inventory 9 666M 0 21 630M 0 20 916M 9 366M
otherCurrentAssets 1 239M 0 267M 0 -7 965M 3 975M
totalCurrentAssets 30 655M 7 993M 30 243M 0 34 111M 28 646M
propertyPlantEquipmentNet 11 814M 0 11 527M 0 11 684M 11 642M
goodwill 49 404M 0 0 0 49 892M 50 555M
intangibleAssets 73 573M 0 0 0 21 640M 21 978M
goodwillAndIntangibleAssets 73 573M 0 73 833M 0 69 395M 72 533M
longTermInvestments 3 257M 0 9 510M 0 9 153M 2 644M
taxAssets 6 427M 0 0 0 5 381M 4 796M
otherNonCurrentAssets 738M -7 993M 240M 0 -5 139M 1 565M
totalNonCurrentAssets 95 809M -7 993M 95 110M 0 90 474M 93 180M
otherAssets 0 0 0 0 0 0
totalAssets 126 464M 0 125 353M 0 124 585M 121 826M
accountPayables 7 328M 0 19 282M 0 18 834M 6 558M
shortTermDebt 2 320M 0 4 947M 0 4 451M 3 294M
taxPayables 597M 0 377M 0 574M 443M
deferredRevenue 597M 0 377M 0 264M 0
otherCurrentLiabilities 13 949M 0 191M 0 425M 12 225M
totalCurrentLiabilities 24 194M 0 24 797M 0 23 974M 22 077M
longTermDebt 14 347M 0 16 080M 0 16 761M 17 943M
deferredRevenueNonCurrent 1 755M 0 9 016M 0 0 0
deferredTaxLiabilitiesNonCurrent 1 857M 0 1 950M 0 1 344M 1 550M
otherNonCurrentLiabilities 9 958M 0 563M 0 8 994M 18 593M
totalNonCurrentLiabilities 27 917M 0 27 609M 0 27 099M 28 445M
otherLiabilities 0 0 0 0 497M 0
capitalLeaseObligations 1 755M 0 2 092M 0 2 181M 2 232M
totalLiabilities 52 111M 0 52 406M 0 51 570M 50 522M
preferredStock 0 0 0 0 0 0
commonStock 2 530M 0 2 525M 0 2 522M 2 531M
retainedEarnings 67 499M 0 0 0 0 0
accumulatedOtherComprehensiveIncomeLoss 4 882M 72 629M 0 0 68 185M 64 470M
othertotalStockholdersEquity -871M 318M 70 104M 0 2 437M 3 950M
totalStockholdersEquity 74 040M 72 947M 72 629M 0 73 144M 70 951M
totalEquity 74 353M 72 947M 72 947M 0 73 512M 70 951M
totalLiabilitiesAndStockholdersEquity 126 464M 72 947M 125 353M 0 124 585M 121 473M
minorityInterest 313M 0 318M 0 368M 0
totalLiabilitiesAndTotalEquity 126 464M 72 947M 125 353M 0 124 585M 121 473M
totalInvestments 3 257M 15 986M 9 510M 0 9 817M 2 644M
totalDebt 18 422M 0 21 027M 0 21 212M 21 237M
netDebt 9 712M 7 993M 13 034M 0 8 476M 14 338M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2020 q4 2020 q3
date 2023-12-31 2023-09-30 2023-06-30 2020-12-31 2020-09-30
symbol SNY SNY SNY SNY SNY
reportedCurrency EUR EUR EUR EUR EUR
cik 0 0 1M 1M 1M
fillingDate 2023-12-31 2023-09-30 2023-07-28 2021-03-04 2020-09-30
acceptedDate 2023-12-29 19:00:00 2023-09-29 20:00:00 2023-07-28 07:00:01 2021-03-04 10:22:29 2020-09-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2020.000 2020.000
period Q4 Q3 Q2 Q4 Q3
netIncome 1 970M 2 525M 1 435M 1 081M 1 952M
depreciationAndAmortization 2 991M 0 0 0 0
deferredIncomeTax -524M 0 0 0 0
stockBasedCompensation 283M 0 160M 0 0
changeInWorkingCapital 1 583M 0 0 0 0
accountsReceivables -182M 0 0 0 0
inventory 334M 0 0 0 0
accountsPayables -95M 0 0 0 0
otherWorkingCapital 1 526M 0 0 0 0
otherNonCashItems 6 600M -2 525M -1 595M -1 081M -1 952M
netCashProvidedByOperatingActivities 6 695M 0 160M 0 0
investmentsInPropertyPlantAndEquipment -2 108M 0 0 0 0
acquisitionsNet 437M 0 0 0 0
purchasesOfInvestments -1 483M 0 0 0 0
salesMaturitiesOfInvestments 27M 0 0 0 0
otherInvestingActivites 0 0 0 0 0
netCashUsedForInvestingActivites -3 127M 0 0 0 0
debtRepayment -2 622M 0 0 0 0
commonStockIssued 164M 0 0 0 0
commonStockRepurchased -230M 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites -12M 0 0 0 0
netCashUsedProvidedByFinancingActivities -2 838M 0 0 0 0
effectOfForexChangesOnCash -13M 0 0 0 0
netChangeInCash 717M 0 160M 0 0
cashAtEndOfPeriod 8 710M 0 160M 0 0
cashAtBeginningOfPeriod 7 993M 0 0 0 0
operatingCashFlow 6 695M 0 160M 0 0
capitalExpenditure -2 108M 0 0 0 0
freeCashFlow 4 587M 0 160M 0 0
link Link Link Link Link
finalLink Link Link Link Link

Earning call transcript

2023 q4
2024-02-01 ET (fiscal 2023 q4)
2023 q3
2023-10-27 ET (fiscal 2023 q3)
2023 q2
2023-07-28 ET (fiscal 2023 q2)
2023 q1
2023-04-27 ET (fiscal 2023 q1)
2022 q4
2023-02-03 ET (fiscal 2022 q4)
2022 q3
2022-10-28 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-25 05:30 ET
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
2024-04-25 05:30 ET
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
2024-04-23 05:00 ET
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
2024-04-23 05:00 ET
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
2024-04-17 05:00 ET
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
2024-04-17 05:00 ET
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
2024-04-12 18:05 ET
Sanofi: Information concerning the total number of voting rights and shares - March 2024
2024-04-08 16:00 ET
Sanofi - AGM 30.04.2024 - Availability of Preparatory documents
2024-04-05 08:15 ET
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
2024-03-22 06:30 ET
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
2024-03-22 06:30 ET
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
2024-03-15 19:04 ET
Sanofi: Information concerning the total number of voting rights and shares - February 2024
2024-03-11 06:00 ET
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2024-03-11 06:00 ET
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2024-02-24 14:51 ET
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
2024-02-24 14:51 ET
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
2024-02-23 17:45 ET
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
2024-02-23 17:45 ET
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
2024-02-23 06:00 ET
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
2024-02-23 06:00 ET
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
2024-02-22 18:02 ET
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
2024-02-22 18:02 ET
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
2024-02-20 22:40 ET
Sanofi: Information concerning the total number of voting rights and shares - January 2024
2024-02-20 13:30 ET
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
2024-02-16 06:00 ET
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
2024-02-16 06:00 ET
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
2024-02-15 13:00 ET
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
2024-02-15 13:00 ET
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
2024-02-06 13:10 ET
CytoReason’s AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development
2024-02-05 07:00 ET
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
2024-02-05 07:00 ET
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
2024-02-01 06:30 ET
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
2024-02-01 06:30 ET
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
2024-02-01 06:30 ET
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
2024-02-01 06:30 ET
Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee
2024-01-29 13:00 ET
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
2024-01-25 19:30 ET
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
2024-01-25 19:30 ET
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
2024-01-23 06:30 ET
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
2024-01-23 06:30 ET
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
2024-01-23 06:00 ET
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
2024-01-17 21:57 ET
Sanofi: Information concerning the total number of voting rights and shares - December 2023
2024-01-09 06:30 ET
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
2024-01-09 06:30 ET
Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
2024-01-03 12:00 ET
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
2023-12-21 06:30 ET
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
2023-12-21 06:30 ET
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
2023-12-18 20:59 ET
Sanofi: Information concerning the total number of voting rights and shares - November 2023
2023-12-15 06:30 ET
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
2023-12-15 06:30 ET
Press Release: Availability of the Q4 2023 Memorandum for modelling purposes
2023-12-15 06:00 ET
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
2023-12-15 06:00 ET
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
2023-12-11 21:08 ET
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
2023-12-11 21:08 ET
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics
2023-12-11 00:30 ET
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
2023-12-11 00:30 ET
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
2023-12-07 06:35 ET
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
2023-12-07 06:35 ET
Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant
2023-12-07 02:30 ET
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
2023-12-07 02:30 ET
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
2023-11-30 13:30 ET
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
2023-11-27 06:30 ET
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
2023-11-27 06:30 ET
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
2023-11-23 17:00 ET
Sanofi: Information concerning the total number of voting rights and shares - October 2023
2023-11-02 16:15 ET
Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities
2023-11-01 11:00 ET
Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.
2023-10-27 05:31 ET
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
2023-10-27 05:31 ET
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
2023-10-27 05:30 ET
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
2023-10-27 05:30 ET
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
2023-10-22 19:00 ET
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
2023-10-22 19:00 ET
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
2023-10-19 10:00 ET
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
2023-10-19 10:00 ET
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
2023-10-18 08:45 ET
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
2023-10-18 08:45 ET
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
2023-10-17 18:18 ET
Sanofi: Information concerning the total number of voting rights and shares - September 2023
2023-10-17 13:00 ET
Sanofi Bridging the Gap between the Homeless and Society via Futsal
2023-10-13 14:00 ET
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2023-10-13 14:00 ET
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2023-10-10 12:00 ET
Stagwell's (STGW) The Harris Poll Unveils First-of-its-kind Global Hemophilia Survey on the Daily Challenges for Patients, Caregivers, and Providers
2023-10-04 05:07 ET
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
2023-10-04 05:00 ET
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
2023-10-04 05:00 ET
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
2023-10-03 05:30 ET
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
2023-10-03 05:30 ET
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
2023-09-26 05:30 ET
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
2023-09-26 05:30 ET
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
2023-09-25 07:00 ET
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
2023-09-25 07:00 ET
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
2023-09-22 05:30 ET
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes
2023-09-19 06:30 ET
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
2023-09-19 06:30 ET
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
2023-09-14 10:00 ET
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
2023-09-13 12:15 ET
Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu
2023-09-11 18:02 ET
Sanofi: Information concerning the total number of voting rights and shares - August 2023
2023-08-31 05:30 ET
Press Release: Sanofi announces changes to its Executive Committee
2023-08-31 05:30 ET
Press Release: Sanofi announces changes to its Executive Committee
2023-08-15 19:24 ET
Sanofi: Information concerning the total number of voting rights and shares - July 2023
2023-08-03 19:21 ET
Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
2023-08-03 19:21 ET
Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
2023-07-28 11:22 ET
Press release: Online availability of Sanofi’s half-year financial report for 2023
2023-07-28 11:22 ET
Press release: Online availability of Sanofi’s half-year financial report for 2023
2023-07-28 05:32 ET
Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
2023-07-28 05:32 ET
Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
2023-07-28 05:30 ET
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
2023-07-28 05:30 ET
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
2023-07-25 12:00 ET
Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
2023-07-20 12:00 ET
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
2023-07-18 16:29 ET
Sanofi: Information concerning the total number of voting rights and shares – June 2023
2023-07-17 17:00 ET
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
2023-07-17 17:00 ET
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
2023-07-17 15:45 ET
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
2023-06-29 05:30 ET
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
2023-06-29 05:30 ET
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
2023-06-27 05:30 ET
Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
2023-06-27 05:30 ET
Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
2023-06-25 14:30 ET
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
2023-06-25 14:30 ET
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
2023-06-22 05:30 ET
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
2023-06-22 05:30 ET
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
2023-06-20 17:43 ET
Sanofi: Information concerning the total number of voting rights and shares - May 2023
2023-06-20 05:30 ET
Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
2023-06-20 05:30 ET
Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
2023-06-13 12:00 ET
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
2023-06-13 12:00 ET
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
2023-06-08 21:19 ET
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
2023-06-08 21:19 ET
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
2023-06-01 05:30 ET
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan  
2023-06-01 05:30 ET
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan  
2023-05-31 05:00 ET
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
2023-05-31 05:00 ET
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
2023-05-25 16:10 ET
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
2023-05-25 16:10 ET
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
2023-05-21 18:17 ET
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
2023-05-21 18:17 ET
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
2023-05-18 15:55 ET
Sanofi Applauds Supreme Court Ruling Supporting Scientific Innovation by Striking Down Amgen's Asserted PCSK9 Patent Claims in Amgen v Sanofi
2023-05-17 20:01 ET
Sanofi: Information concerning the total number of voting rights and shares – April 2023
2023-05-12 08:50 ET
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
2023-05-12 08:50 ET
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
2023-05-04 06:00 ET
Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS
2023-05-01 10:00 ET
Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
2023-04-27 12:40 ET
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
2023-04-27 12:40 ET
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
2023-04-27 05:30 ET
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
2023-04-27 05:30 ET
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
2023-04-26 06:00 ET
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
2023-04-26 06:00 ET
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
2023-04-23 23:01 ET
Sanofi Announces Launch of AVAXIM® Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in Children Aged 12 Months to 15 Years
2023-04-19 19:05 ET
Sanofi: Information concerning the total number of voting rights and shares - March 2023
2023-04-11 06:00 ET
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
2023-04-11 06:00 ET
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
2023-04-10 20:15 ET
Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
2023-04-10 20:15 ET
Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
2023-04-04 14:34 ET
Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines
2023-04-04 05:00 ET
Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
2023-04-04 05:00 ET
Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
2023-03-30 05:30 ET
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
2023-03-30 05:30 ET
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
2023-03-23 06:00 ET
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 
2023-03-23 06:00 ET
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 
2023-03-21 06:00 ET
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 
2023-03-21 06:00 ET
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 
2023-03-18 14:00 ET
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
2023-03-18 14:00 ET
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
2023-03-16 20:06 ET
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
2023-03-16 20:06 ET
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
2023-03-14 18:27 ET
Information concerning the total number of voting rights and shares – February 2023
2023-03-13 06:00 ET
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
2023-03-13 06:00 ET
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
2023-03-07 06:00 ET
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
2023-03-07 06:00 ET
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
2023-03-02 07:00 ET
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
2023-03-02 07:00 ET
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
2023-02-24 16:16 ET
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
2023-02-24 16:16 ET
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
2023-02-24 15:31 ET
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
2023-02-24 15:31 ET
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
2023-02-23 21:00 ET
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
2023-02-23 21:00 ET
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
2023-02-15 18:00 ET
Sanofi: Information concerning the total number of voting rights and shares – January 2023
2023-02-13 07:30 ET
Press Release: Sanofi announces change in R&D leadership
2023-02-13 07:30 ET
Press Release: Sanofi announces change in R&D leadership
2023-02-03 06:30 ET
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
2023-02-03 06:30 ET
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

SEC forms

Show financial reports only

SEC form 6
2024-04-25 10:49 ET
Sanofi published news for 2024 q1
SEC form 6
2024-04-25 10:49 ET
Sanofi published news for 2024 q1
SEC form 6
2024-03-20 14:07 ET
Sanofi published news for 2023 q4
SEC form 6
2024-03-20 14:07 ET
Sanofi published news for 2023 q4
SEC form 6
2024-02-27 11:35 ET
Sanofi published news for 2023 q4
SEC form 6
2024-02-27 11:35 ET
Sanofi published news for 2023 q4
SEC form 6
2024-02-27 11:35 ET
Sanofi published news for 2023 q4
SEC form 6
2024-02-27 11:35 ET
Sanofi published news for 2023 q4
SEC form 6
2024-02-27 11:35 ET
Sanofi published news for 2023 q4
SEC form 6
2024-02-27 11:35 ET
Sanofi published news for 2023 q4
SEC form 6
2024-01-23 07:23 ET
Sanofi published news for 2023 q4
SEC form 6
2024-01-23 07:23 ET
Sanofi published news for 2023 q4
SEC form 6
2024-01-17 13:49 ET
Sanofi published news for 2023 q4
SEC form 6
2024-01-17 13:49 ET
Sanofi published news for 2023 q4
SEC form 6
2023-12-27 11:18 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-27 11:18 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-20 10:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-20 10:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-20 10:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-20 10:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-20 10:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-20 10:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-01 12:19 ET
Sanofi published news for 2023 q3
SEC form 6
2023-12-01 12:19 ET
Sanofi published news for 2023 q3
SEC form 6
2023-10-27 12:39 ET
Sanofi published news for 2023 q3
SEC form 6
2023-10-27 11:33 ET
Sanofi published news for 2023 q3
SEC form 6
2023-10-26 07:16 ET
Sanofi published news for 2023 q3
SEC form 6
2023-10-20 14:31 ET
Sanofi published news for 2023 q3
SEC form 6
2023-10-11 06:05 ET
Sanofi published news for 2023 q3
SEC form 6
2023-09-27 06:06 ET
Sanofi published news for 2023 q2
SEC form 6
2023-09-05 06:19 ET
Sanofi published news for 2023 q2
SEC form 6
2023-07-28 15:35 ET
Sanofi published news for 2023 q2
SEC form 6
2023-07-28 09:18 ET
Sanofi published news for 2023 q2
SEC form 6
2023-07-28 07:00 ET
Sanofi published news for 2023 q2
SEC form 6
2023-07-24 12:43 ET
Sanofi published news for 2023 q2
SEC form 6
2023-07-05 08:43 ET
Sanofi published news for 2023 q2
SEC form 6
2023-06-28 14:32 ET
Sanofi published news for 2023 q1
SEC form 6
2023-06-28 14:31 ET
Sanofi published news for 2023 q1
SEC form 6
2023-06-20 10:18 ET
Sanofi published news for 2023 q1
SEC form 6
2023-06-02 10:53 ET
Sanofi published news for 2023 q1
SEC form 6
2023-05-23 13:01 ET
Sanofi published news for 2023 q1
SEC form 6
2023-04-11 13:02 ET
Sanofi published news for 2023 q1
SEC form 6
2023-03-23 16:00 ET
Sanofi published news for 2022 q4
SEC form 6
2023-03-14 12:05 ET
Sanofi published news for 2022 q4
SEC form 6
2023-03-13 07:38 ET
Sanofi published news for 2022 q4
SEC form 6
2023-03-06 11:57 ET
Sanofi published news for 2022 q4
SEC form 6
2023-02-24 17:20 ET
Sanofi reported for 2022 q4
SEC form 6
2023-02-24 10:25 ET
Sanofi published news for 2022 q4
SEC form 6
2023-02-21 12:52 ET
Sanofi published news for 2022 q4
SEC form 6
2023-02-03 11:40 ET
Sanofi published news for 2022 q4
SEC form 6
2023-01-31 13:03 ET
Sanofi published news for 2022 q4
SEC form 6
2023-01-17 14:07 ET
Sanofi published news for 2022 q4
SEC form 6
2022-12-20 06:13 ET
Sanofi published news for 2022 q3
SEC form 6
2022-12-02 10:40 ET
Sanofi published news for 2022 q3
SEC form 6
2022-11-21 10:05 ET
Sanofi published news for 2022 q3
SEC form 6
2022-11-15 15:01 ET
Sanofi published news for 2022 q3
SEC form 6
2022-11-10 14:00 ET
Sanofi published news for 2022 q3
SEC form 6
2022-10-28 11:16 ET
Sanofi published news for 2022 q3
SEC form 6
2022-10-17 13:35 ET
Sanofi published news for 2022 q3
SEC form 6
2022-10-03 11:24 ET
Sanofi published news for 2022 q3
SEC form 6
2022-09-22 09:49 ET
Sanofi published news for 2022 q2
SEC form 6
2022-09-12 07:07 ET
Sanofi published news for 2022 q2
SEC form 6
2022-09-02 09:44 ET
Sanofi published news for 2022 q2
SEC form 6
2022-08-17 13:18 ET
Sanofi published news for 2022 q2
SEC form 6
2022-08-11 15:24 ET
Sanofi published news for 2022 q2
SEC form 6
2022-08-08 16:27 ET
Sanofi published news for 2022 q2
SEC form 6
2022-07-28 10:12 ET
Sanofi published news for 2022 q2
SEC form 6
2022-07-28 00:00 ET
Sanofi published news for 2022 q2
SEC form 6
2022-07-20 12:38 ET
Sanofi published news for 2022 q2
SEC form 6
2022-07-13 13:40 ET
Sanofi published news for 2022 q2
SEC form 6
2022-07-08 11:01 ET
Sanofi published news for 2022 q2
SEC form 6
2022-06-30 12:10 ET
Sanofi published news for 2022 q1
SEC form 6
2022-06-29 11:48 ET
Sanofi published news for 2022 q1
SEC form 6
2022-06-29 11:46 ET
Sanofi published news for 2022 q1
SEC form 6
2022-06-28 15:59 ET
Sanofi published news for 2022 q1
SEC form 6
2022-06-16 13:20 ET
Sanofi published news for 2022 q1
SEC form 6
2022-06-13 14:56 ET
Sanofi published news for 2022 q1
SEC form 6
2022-06-07 14:51 ET
Sanofi published news for 2022 q1
SEC form 6
2022-05-31 10:56 ET
Sanofi published news for 2022 q1
SEC form 6
2022-05-25 13:53 ET
Sanofi published news for 2022 q1
SEC form 6
2022-05-17 15:20 ET
Sanofi published news for 2022 q1
SEC form 6
2022-05-16 13:45 ET
Sanofi published news for 2022 q1
SEC form 6
2022-05-09 14:29 ET
Sanofi published news for 2022 q1
SEC form 6
2022-04-29 12:38 ET
Sanofi published news for 2022 q1
SEC form 6
2022-04-28 12:16 ET
Sanofi published news for 2022 q1
SEC form 6
2022-04-19 11:32 ET
Sanofi published news for 2022 q1
SEC form 6
2022-04-07 15:13 ET
Sanofi published news for 2022 q1
SEC form 6
2022-04-04 11:21 ET
Sanofi published news for 2022 q1
SEC form 6
2022-04-01 13:40 ET
Sanofi published news for 2022 q1
SEC form 6
2022-03-31 12:12 ET
Sanofi published news for 2021 q4
SEC form 6
2022-03-30 13:44 ET
Sanofi published news for 2021 q4
SEC form 6
2022-03-22 14:29 ET
Sanofi published news for 2021 q4
SEC form 6
2022-03-15 15:52 ET
Sanofi published news for 2021 q4
SEC form 6
2022-03-04 16:20 ET
Sanofi published news for 2021 q4
SEC form 6
2022-02-24 17:14 ET
Sanofi published news for 2021 q4
SEC form 6
2022-02-23 13:00 ET
Sanofi published news for 2021 q4
SEC form 6
2022-02-14 14:07 ET
Sanofi published news for 2021 q4
SEC form 6
2022-02-04 13:29 ET
Sanofi published news for 2021 q4
SEC form 6
2022-02-04 09:56 ET
Sanofi published news for 2021 q4
SEC form 6
2022-01-24 13:41 ET
Sanofi published news for 2021 q4
SEC form 6
2022-01-12 13:47 ET
Sanofi published news for 2021 q4
SEC form 6
2021-12-21 13:28 ET
Sanofi published news for 2021 q3
SEC form 6
2021-12-15 14:50 ET
Sanofi published news for 2021 q3
SEC form 6
2021-12-06 14:45 ET
Sanofi published news for 2021 q3
SEC form 6
2021-11-22 12:42 ET
Sanofi published news for 2021 q3
SEC form 6
2021-11-09 16:53 ET
Sanofi published news for 2021 q3
SEC form 6
2021-10-28 11:19 ET
Sanofi published news for 2021 q3
SEC form 6
2021-10-26 17:08 ET
Sanofi published news for 2021 q3
SEC form 6
2021-10-15 14:05 ET
Sanofi published news for 2021 q3
SEC form 6
2021-10-07 13:08 ET
Sanofi published news for 2021 q3
SEC form 6
2021-09-30 06:18 ET
Sanofi published news for 2021 q2
SEC form 6
2021-09-23 13:54 ET
Sanofi published news for 2021 q2
SEC form 6
2021-09-14 09:38 ET
Sanofi published news for 2021 q2
SEC form 6
2021-09-10 15:23 ET
Sanofi published news for 2021 q2
SEC form 6
2021-09-08 08:01 ET
Sanofi published news for 2021 q2
SEC form 6
2021-08-09 14:54 ET
Sanofi published news for 2021 q2
SEC form 6
2021-08-03 17:19 ET
Sanofi published news for 2021 q2
SEC form 6
2021-08-02 17:03 ET
Sanofi published news for 2021 q2
SEC form 6
2021-07-30 16:01 ET
Sanofi published news for 2021 q2
SEC form 6
2021-07-29 09:52 ET
Sanofi published news for 2021 q2
SEC form 6
2021-07-29 00:00 ET
Sanofi published news for 2021 q2
SEC form 6
2021-07-16 12:06 ET
Sanofi published news for 2021 q2
SEC form 6
2021-06-30 17:17 ET
Sanofi published news for 2021 q1
SEC form 6
2021-06-29 12:30 ET
Sanofi published news for 2021 q1
SEC form 6
2021-06-29 12:01 ET
Sanofi published news for 2021 q1
SEC form 6
2021-06-24 10:40 ET
Sanofi published news for 2021 q1
SEC form 6
2021-06-16 12:57 ET
Sanofi published news for 2021 q1
SEC form 6
2021-06-08 13:31 ET
Sanofi published news for 2021 q1
SEC form 6
2021-06-02 11:46 ET
Sanofi published news for 2021 q1
SEC form 6
2021-05-21 16:16 ET
Sanofi published news for 2021 q1
SEC form 6
2021-05-13 08:09 ET
Sanofi published news for 2021 q1
SEC form 6
2021-05-11 10:01 ET
Sanofi published news for 2021 q1
SEC form 6
2021-05-03 17:14 ET
Sanofi published news for 2021 q1
SEC form 6
2021-04-28 09:49 ET
Sanofi published news for 2021 q1
SEC form 6
2021-04-23 13:01 ET
Sanofi published news for 2021 q1
SEC form 6
2021-04-13 14:56 ET
Sanofi published news for 2021 q1
SEC form 6
2021-04-02 14:21 ET
Sanofi published news for 2021 q1
SEC form 6
2021-03-19 15:49 ET
Sanofi published news for 2020 q4
SEC form 6
2021-03-08 16:20 ET
Sanofi published news for 2020 q4
SEC form 6
2021-03-04 10:22 ET
Sanofi published news for 2020 q4
SEC form 6
2021-02-23 16:26 ET
Sanofi published news for 2020 q4
SEC form 6
2021-02-19 13:48 ET
Sanofi published news for 2020 q4
SEC form 6
2021-02-11 15:17 ET
Sanofi published news for 2020 q4
SEC form 6
2021-02-05 12:16 ET
Sanofi published news for 2020 q4
SEC form 6
2021-01-19 08:50 ET
Sanofi published news for 2020 q4
SEC form 6
2021-01-12 14:57 ET
Sanofi published news for 2020 q4
SEC form 6
2020-12-18 14:13 ET
Sanofi published news for 2020 q3
SEC form 6
2020-12-11 15:25 ET
Sanofi published news for 2020 q3
SEC form 6
2020-12-03 13:40 ET
Sanofi published news for 2020 q3
SEC form 6
2020-11-25 12:40 ET
Sanofi published news for 2020 q3
SEC form 6
2020-11-19 13:24 ET
Sanofi published news for 2020 q3
SEC form 6
2020-11-04 15:27 ET
Sanofi published news for 2020 q3
SEC form 6
2020-10-30 17:09 ET
Sanofi published news for 2020 q3
SEC form 6
2020-10-29 10:22 ET
Sanofi published news for 2020 q3
SEC form 6
2020-10-27 13:03 ET
Sanofi published news for 2020 q3
SEC form 6
2020-10-16 17:06 ET
Sanofi published news for 2020 q3
SEC form 6
2020-10-06 13:24 ET
Sanofi published news for 2020 q3
SEC form 6
2020-10-01 14:08 ET
Sanofi published news for 2020 q3